Table 3

Univariate analyses (Cox model) of progression

Hazard ratio95% CIP
Sex (female vs male) 1.06 0.44-2.56 .895 
Age (> 60 y vs ≤ 60 y) 2.04 0.84-4.92 .114 
Stage (III or IV vs I or II) 2.51 0.84-7.52 .101 
ECOG PS (≥ 2 vs 0 or 1) 2.15 0.89-5.21 .089 
LDH (> 450 U/L vs ≤ 450 U/L) 6.16 2.04-18.51 .001 
Extranodal involvement (≥ 2 vs 0 or 1) 2.70 1.11-6.53 .028 
aaIPI (≥ 3 vs 0-2) 6.05 2.18-16.82 .001 
Bulky disease (yes vs no) 1.63 0.67-3.99 .286 
Bone marrow involvement (yes vs no) 2.41 0.98-5.89 .055 
Spleen involvement (yes vs no) 1.97 0.71-5.42 .191 
Radiotherapy (yes vs no) 0.57 0.13-2.45 .448 
G-CSF administration (yes vs no) 2.39 0.32-18.14 .398 
No. of R-CHOP cycles at I-PET (3 or 4 vs 2) 1.06 0.42-2.67 .901 
R-CHOP cycle interval (21 vs 14) 1.07 0.44-2.63 .878 
I-PET result (positive vs negative) 2.45 1.01-5.93 .047 
F-PET result (positive vs negative) 5.97 2.19-16.28 < .001 
Clinical response (no CR vs CR) 14.28 5.26-49.88 < .001 
Hazard ratio95% CIP
Sex (female vs male) 1.06 0.44-2.56 .895 
Age (> 60 y vs ≤ 60 y) 2.04 0.84-4.92 .114 
Stage (III or IV vs I or II) 2.51 0.84-7.52 .101 
ECOG PS (≥ 2 vs 0 or 1) 2.15 0.89-5.21 .089 
LDH (> 450 U/L vs ≤ 450 U/L) 6.16 2.04-18.51 .001 
Extranodal involvement (≥ 2 vs 0 or 1) 2.70 1.11-6.53 .028 
aaIPI (≥ 3 vs 0-2) 6.05 2.18-16.82 .001 
Bulky disease (yes vs no) 1.63 0.67-3.99 .286 
Bone marrow involvement (yes vs no) 2.41 0.98-5.89 .055 
Spleen involvement (yes vs no) 1.97 0.71-5.42 .191 
Radiotherapy (yes vs no) 0.57 0.13-2.45 .448 
G-CSF administration (yes vs no) 2.39 0.32-18.14 .398 
No. of R-CHOP cycles at I-PET (3 or 4 vs 2) 1.06 0.42-2.67 .901 
R-CHOP cycle interval (21 vs 14) 1.07 0.44-2.63 .878 
I-PET result (positive vs negative) 2.45 1.01-5.93 .047 
F-PET result (positive vs negative) 5.97 2.19-16.28 < .001 
Clinical response (no CR vs CR) 14.28 5.26-49.88 < .001 
View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal